Medical School or Training
University of Hong Kong, 1977
Queen Mary Hospital, Internal Medicine, 1981
Hepatology, Royal Free Hospital, 1983
Hepatitis B: Ongoing projects include:
a. role of viral factors in disease progression
b. adherence to hepatitis B medications in clinical practice and methods to improve adherence and response to hepatitis B treatment
c. safety and efficacy of new antiviral therapies for hepatitis B
d. outcomes of patients after liver transplantation.
Hepatitis C: Ongoing projects include:
a. incidence and risk factors associated with hepatocellular carcinoma in the US
b. biomarkers for the early diagnosis of hepatocellular carcinoma
c. genetic factors associated with fibrosis progression
d. models to predict disease progression and hepatocellular carcinoma development
e. safety and efficacy of new antiviral therapies for hepatitis C including interferon-free regimens.
Cirrhosis: Ongoing projects include:
a. functional status of patients with cirrhosis and caregiver burden
b. patient and caregiver education to prevent hospital readmissions and to improve patient outcomes.
Academic office address:
Division of Gastroenterology
Taubman Health Center, Room 3912
1500 East Medical Center Drive, SPC 5362
Ann Arbor, 48109-5362
Academic office telephone: 734-936-7511
Academic office fax: 734-936-7392
Anna Suk-Fong Lok, MD is the Alice Lohrman Andrews Research Professor in Hepatology in the Department of Internal Medicine, University of Michigan Health System in Ann Arbor, Michigan. Dr. Lok is also Director of Clinical Hepatology and Associate Chair for Clinical Research in the Department of Internal Medicine.
Dr. Lok obtained her medical degree from the University of Hong Kong and her hepatology training under the late Dame Sheila Sherlock at the Royal Free Hospital in London, UK. She was on the faculty at the University of Hong Kong until she moved to the United States in 1992.
Dr. Lok's research focuses on the natural history and treatment of hepatitis B and C, and the prevention of liver cancer. Her research is funded by the National Institutes of Health, federal and private foundations, and various pharmaceutical companies. She has published more than 350 papers on viral hepatitis and liver diseases and is the coauthor of the American Association for the Study of Liver Diseases Association Guidelines on Hepatitis B. Dr. Lok has trained more than 30 fellows and junior faculty from all over the world, some of whom have risen to the ranks of full professors and directors of liver programs in their home country. She received a Distinguished Mentor Award from the Michigan Institute of Clinical and Health Research in 2012.
Dr. Lok has received many awards throughout her career. She has been included in the list of "Best Doctors" and "Who's Who" for many years. Other recent awards include the Distinguished Scientist Award from the Hepatitis B Foundation in 2008, the Distinguished Women Scientist Award from the American Gastroenterological Association in 2008, and the Distinguished Service Award from the American Association for the Study of Liver Diseases in 2011.
Dr. Lok served as an Associate Editor of HEPATOLOGY in 2001-2006 and a Co-Editor of Journal of Viral Hepatitis in 2007-2009. She is currently a Senior Associate Editor of GASTROENTEROLOGY.
Dr. Lok is a member of the executive board of the Asian Health Foundation, a nonprofit organization focused on improving the health of Asian Americans.
Languages: English, Cantonese